Connor, Clark & Lunn Investment Management (CC&L)
LAB icon

Connor, Clark & Lunn Investment Management (CC&L)’s Standard BioTools LAB Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-249,944
Closed -$980K – 1129
2021
Q4 		$980K Buy
249,944
+5,828
+2% +$27.3K ﹤0.01% 682
2021
Q3 		$1.61M Buy
244,116
+233,251
+2,147% +$1.53M 0.01% 560
2021
Q2 		$67K Sell
10,865
-138,650
-93% -$741K ﹤0.01% 950
2021
Q1 		$676K Sell
149,515
-143,742
-49% -$790K ﹤0.01% 754
2020
Q4 		$1.76M Buy
293,257
+4,416
+2% +$29K 0.01% 529
2020
Q3 		$2.15M Buy
288,841
+166,717
+137% +$1.15M 0.01% 466
2020
Q2 		$490K Sell
122,124
-31,283
-20% -$109K ﹤0.01% 761
2020
Q1 		$390K Buy
+153,407
New +$504K ﹤0.01% 751
2019
Q3 		– Sell
-63,201
Closed -$779K – 1026
2019
Q2 		$779K Sell
63,201
-25,955
-29% -$331K 0.01% 623
2019
Q1 		$1.19M Buy
89,156
+1,224
+1% +$12.9K 0.01% 497
2018
Q4 		$758K Sell
87,932
-92,100
-51% -$717K 0.01% 608
2018
Q3 		$1.35M Sell
180,032
-2,063
-1% -$14.7K 0.01% 520
2018
Q2 		$1.08M Sell
182,095
-6,700
-4% -$38.2K 0.01% 597
2018
Q1 		$1.1M Buy
188,795
+43,950
+30% +$289K 0.01% 475
2017
Q4 		$853K Buy
144,845
+34,519
+31% +$189K 0.01% 539
2017
Q3 		$556K Buy
110,326
+37,201
+51% +$156K ﹤0.01% 629
2017
Q2 		$295K Buy
73,125
+52,625
+257% +$250K ﹤0.01% 684
2017
Q1 		$117K Sell
20,500
-1,600
-7% -$10.1K ﹤0.01% 841
2016
Q4 		$161K Sell
22,100
-35,775
-62% -$225K ﹤0.01% 811
2016
Q3 		$464K Buy
57,875
+11,100
+24% +$102K ﹤0.01% 593
2016
Q2 		$422K Sell
46,775
-2,375
-5% -$22.3K ﹤0.01% 613
2016
Q1 		$397K Sell
49,150
-300
-0.6% -$2.16K ﹤0.01% 603
2015
Q4 		$535K Buy
+49,450
New +$486K ﹤0.01% 531

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s LAB Position: Q1 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Standard BioTools (LAB) in Q1 2022, closing a stake of 249,944 shares — an estimated $980K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in LAB in Q4 2015 and held it in 23 quarters. The position peaked at $2.15M in Q3 2020. 109 funds tracked by Wall St. Rank hold LAB as of Q1 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Standard BioTools position as of Q1 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 249,944 Standard BioTools shares in Q1 2022, an estimated $980K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Standard BioTools in Q4 2015 and held it in 23 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Standard BioTools position peaked at $2.15M in Q3 2020.
  • 109 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2022, filed 12 May 2022.